Study of Alzheimer’s Disease in Down Syndrome (LIFE-DSR)
This is an observational, multicenter, longitudinal cohort study to characterize adults with Down syndrome ages 25 years and above enrolled at specialized care centers. The aim is to assess changes in cognition, behavior, function, and health over approximately 24 months.
Blood will be collected for the development of plasma Alzheimer’s disease biomarkers useful in the Down syndrome population.
Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome (3 Star)
This is a prospective multi-center, placebo controlled, double-blind and randomized dose escalation study of 2 doses of ACI-24 versus Placebo over 24 months with a total of 21 visits.
All subjects will receive the study medication (ACI-24 or Placebo) 7 times via s.c. injection (12 months) and will be followed up for 12 months after the last dose with a final safety and efficacy assessment.